dBcAMP Unlocks a New Neuroprotective Pathway: Blocking Cuproptosis to Combat Cerebral Ischemia-Reperfusion Injury
After blood vessels are recanalized in stroke patients, cerebral ischemia-reperfusion injury may still occur, causing continuous damage to brain cells. Clinically, effective neuroprotective drugs remain scarce. A study published in Current Neurovascular Research offers new insight into this challenge: dibutyryl cyclic adenosine monophosphate (dBcAMP) protects damaged neurons by inhibiting cuproptosis, a newly identified form of cell death.
Cuproptosis is triggered by copper ion overload and acts as a key driver of damage in cerebral ischemic injury. The research team carried out mouse studies and in vitro ischemia injury assays on hippocampal neurons. Transcriptomic data show that dBcAMP markedly suppresses cuproptosis-related pathways. Cellular experiments further confirm that dBcAMP lowers excessive intracellular copper accumulation, stabilizes mitochondrial function, and improves the survival of injured neurons.
Previously, dBcAMP was only known to regulate apoptosis. This study reveals its additional biological activity. Beyond cuproptosis inhibition, it modulates inflammation and remodels the extracellular matrix to deliver multi-layered protection.
Nevertheless, the research is still at an early stage. Only male mice were used, with a limited sample size. Industry observers note that dBcAMP has promising development potential. Still, the full molecular cascade requires further investigation, and substantial trials lie ahead before clinical translation.
FOR DETAIL: https://doi.org/10.2174/0115672026458138251211073956
Article from:
